Igor Rakovic, MD is a physician with over 20 years of experience in the pharmaceutical and biotechnology industry, with a strong focus over the past decade on oncology, nuclear medicine, and radioligand therapy. He currently serves as Global Medical Director for Radioligand Therapy at Novartis, where he leads medical strategy and integrated evidence planning for early stage RLT assets across multiple tumor types, including pancreatic, breast, and lung cancer. Dr. Rakovic has extensive experience in medical strategy, evidence generation, patient safety, and medical compliance, and is an advocate of industry–academia collaboration to accelerate clinical development, adoption, and access to innovative therapies.
